Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.

T-DM1 sustained the improvement in invasive disease-free survival over trastuzumab in HER2-positive early breast cancer.

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

Enhertu first secured approval in 2019 for patients with high levels of HER2, a protein that promotes cancer cell growth. In ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

The antibody-drug conjugate improved progression-free survival for patients previously treated with hormone therapy.

A far shorter, simpler, and less toxic treatment protocol for patients with triple-negative breast cancer produced outcomes ...

The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the efficacy of Winrevair (sotatercept-csrk) in treating pulmonary arterial ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

Morgan Stanley analyst Michael Ulz has maintained their neutral stance on ZNTL stock, giving a Hold rating yesterday.Invest with Confidence: ...

Oppenheimer 35 th Annual Healthcare Life Sciences Conference: Zymeworks' management will participate in virtual one-on-one ...

Adjuvant chest wall irradiation should be omitted in most patients meeting the eligibility criteria for SUPREMO,” said Ian Kunkler, MB BChir.